RECHERCHE :   Cancers de la peau
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
AMGEN 20120139: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Tous les types de tumeurs
registre
CHUV
BMS CA224-020 - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Mélanome, cancer de la vessie
I
CHUV
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
CA027-002: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Tumeurs solides avancés
I, II
CHUV
CA045-001: A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
Mélanome métastatique ou non résécable
III
CHUV
CA209-76K: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma
Mélanome de stade IIB/C ( après résection complète)
III
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
CHUV-DO-ATATIL-2016 - Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma
Mélanome
I
CHUV
EORTC 1208 (Minitub): Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
Positive Mélanome positif en ganglion sentinelle (SN)
registre
CHUV
INCMGA 0012-201 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
Cancer métastatique des cellules de Merkel
II
CHUV
MK3475-U02:A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma: Master (KEYNOTE-U02)
Melanoma
I, II
CHUV
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
PEMSYS: An interventional phase II study to a nalyze the modulation of the tumor microenvironment by MK-3475 (pembrolizumab,) using a systems biology approach
Mélanome cutané avancé ou métastatique
II
CHUV